Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Fig. 3

Summary of quantitative data analysis with Random effects or fixed effects SMD (95% CI) estimate with a p-value for analysis of primary efficacy outcomes. *Statistically significant variables at P value < 0.05. a Fasting serum glucose, b hemoglobin A1c, c body weight, d triglyceride, e HDL cholesterol, f LDL cholesterol

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us